The Pfizer/BioNTech was available first so there is more data, but the Oxford/AstraZeneca was mostly used in the older age group. The first thing we can say based on these data, is that when you are offered the second dose, please also take that because its very important. The study was not set up to look at any differences between the two. The numbers were very small and there was uncertainty over their significance, said the researchers. That rose to more than 85% after the second dose.
The Pfizer/BIO-Teck was not available a ready made equal get ready.
( z0 available :ARG2 ( z1 slash :op ( z2 company :name ( z3 name :op "Pfizer" ) ) :op ( z4 company :name ( z5 name :op "navy" ) ) ) :ARG3 ( z6 ready :ARG1 ( z7 you ) :ARG1-of ( z8 make ) :ARG1-of ( z9 ready ) ) :polarity - :rel ( z10 equal ) )
(z0 / available-02
    :ARG2 (z1 / slash
              :op1 (z2 / company
                       :name (z3 / name
                                 :op1 "Pfizer"))
              :op2 (z4 / company
                       :name (z5 / name
                                 :op1 "navy")))
    :ARG3 (z6 / ready-01
              :ARG1 (z7 / you)
              :ARG1-of (z8 / make-01)
              :ARG1-of (z9 / ready-01))
    :polarity -
    :rel (z10 / equal-01))
The Pfizer / BIO - Teck was not available a ready made equal get ready .
z2 :name z3
z3 :op1 1
z1 :op1 z2
z1 :op2 z4
z4 :name z5
z5 :op1 2
z0 :polarity 0
z0 :ARG2 z1
z6 :ARG1 z7
z6 :ARG1-of z8
z6 :ARG1-of z9
z0 :ARG3 z6
z0 :rel z10